FindTrial
Sign In

A clinical trial to study the effects of two drugs, Shringarabhra rasa and Ashwagandha ghanavati in patients with Post COVID-19 Respiratory problems.

An open labelled RCT on role of Virechanottara Rasarasayana effect of Shringarabhra rasa and Ashwagandha ghana vati with Katphaladi kashaya anupana in the management of Shadrupa Rajayakshma with special refference to Post covid-19 Respiratory illness

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/08/045124
Enrollment
40
Registered
2022-08-31
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

None listed

Sponsors

Pandith Taranath Govt Ayurvedic Medical College and Hospital Bellary
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Post covid-19 Respiratory illness patients. 2)Patients age between 20 to 50 year. 3)Patient fit for Rasayana and virechana. 4) Patient irrespective of Religion, sex, socio economic status, occupation etc. 5)Who signed the informed consent.

Exclusion criteria

Exclusion criteria: 1)Patients age less than 20 and more than 50 year. 2)Patients unfit for Rasayana and virechana. 3)Patients having other systemic disease like Respiratory failure, Sepsis.

Design outcomes

Primary

MeasureTime frame
Improvement of quality of life and Immunity in post covid-19 like swasa, kasa, Dourbalya.Assessment done by spirometry and Peak expiratory flow meter readings.Timepoint: 0 to 46th day—

Secondary

MeasureTime frame
Improvement of quality of life and Immunity in post covid-19Timepoint: 61 DAYS—

Countries

India

Contacts

Public ContactDr Muttanna Kamannavara

TGAMC and hospital bellary

dr.fareedabegumshaikh@gmail.com9886478611

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026